×

NRx shares jump 39% on new clinical data testing its experimental COVID-19 drug in the critically ill

Published Oct 14 2021 at 11:24 AM GMT
Key
Points
  • Shares of NRx Pharmaceuticals Inc soared 39.9% in premarket trading on Thursday after the company said new peer-reviewed data published in the Journal of Infectious Diseases and Treatment showed that its experimental COVID-19 therapy improved survival in critically ill patients.
  • The data came from an open-label trial assessing respiratory failure in 21 patients who were too sick to participate in the company's Phase 2b/3 trial evaluating the drug, aviptadil, in COVID-19 patients with respiratory failure.
  • NRx said there were no adverse events, though low blood pressure was reported and managed in two patients.
  • NRx's stock is down 61.3% so far this year, while the broader S&P 500 is up 16.
  • 1%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.




Trending

Stats

  • Published Oct 14, 2021 11:24 AM GMT